Application of flufenamic acid in preparation of polymyxin E antibacterial synergist

The combined use of flufenamic acid and polymyxin E enhanced the antibacterial activity against Salmonella, solved the problem of polymyxin E resistance, improved the therapeutic effect, reduced the bacterial load, and extended the lifespan of polymyxin E.

CN122056860APending Publication Date: 2026-05-19XINJIANG ACADEMY OF AGRI & RECLAMATION SCI +1
0 Cites 0 Cited by

Patent Information

Application Number
CN202610237690.5
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2026-02-28
Publication Date
2026-05-19

AI Technical Summary

Technical Problem

In the current technology, Salmonella's drug resistance is a serious problem, the effectiveness of polymyxin E is affected, there is a lack of effective antibacterial potentiators to restore its sensitivity, and the development of new antibiotics is lagging behind, so there is an urgent need for new treatment strategies.

Method used

When flufenamic acid is used in combination with polymyxin E, it acts as an antibacterial synergist of polymyxin E, significantly enhancing its antibacterial activity against Salmonella, reducing the dosage of polymyxin E, and inhibiting the development of drug resistance.

Benefits of technology

In both in vitro and in vivo environments, the combined use of flufenamic acid and polymyxin E significantly improved the antibacterial effect against Salmonella, increased animal survival rates, reduced bacterial load in the liver, spleen, and kidneys, and prevented polymyxin E resistance.

✦ Generated by Eureka AI based on patent content.
Patent Text Reader

Abstract

The invention relates to the technical field of biological medicine, in particular to application of flufenamic acid in preparation of a polymyxin E antibacterial synergist. The invention discloses an application of flufenamic acid in preparation of a polymyxin E antibacterial synergist, the flufenamic acid has no obvious antibacterial effect on salmonella when being independently used, but the flufenamic acid and polymyxin E can enhance the antibacterial activity of the polymyxin E on the salmonella and reduce the use dosage of the polymyxin E when being jointly used in and out of an animal body, so that the antibacterial effect of the polymyxin E on the salmonella can be enhanced. The antibacterial activity of the polymyxin E on salmonella is enhanced, and the drug resistance of the polymyxin E is inhibited. Flurfenamic acid is approved to be used for other purposes as FDA, and when the flurfenamic acid is combined with polymyxin E, the flurfenamic acid has the characteristic of high safety, and meanwhile, the generation of the drug resistance of the polymyxin E drugs can be effectively avoided. The invention provides a basis for mining a new antibacterial prevention and control strategy for the polymyxin E drug-resistant bacteria.
Need to check novelty before this filing date? Find Prior Art